Abstract

Aim: Cyclophosphamide (CP) is a cytostatic agent, which evokes numerous side effects, including well-known cystitis. Acrolein released during CP biotransformation exerts both urotoxic and nephrotoxic effects, therefore CP may cause renal dysfunction. The aim of the study was to assess kidney function in experimental models of acute and chronic cystitis. Material/Methods: The studies were carried out on 40 rats (4 groups; n = 10), in which acute (single dose of 150 mg/kg CP; group 2) or chronic (four doses of 75 mg/kg CP; group 4) cystitis was induced with appropriate control groups (group 1 and 3). Renal function was assessed with standard (diuresis, urea, creatinine) and new (fatty acid binding protein – FABP and osteopontin) laboratory parameters as well as histopathologically. Results: The histopathological assessment confirmed the presence of acute and chronic cystitis and did not reveal coexisting significant kidney disorders in groups 2 and 4. Group 2 retained urea and creatinine in the blood. Both groups 2 and 4 showed an increase in diurnal diuresis, and a decreased concentration of urea and creatinine was found in the urine, which was accompanied by significant proteinuria. The daily urinary excretion of small-molecule nitrogen compounds did not differ from the values found in the control groups. In addition, both groups 2 and 4 showed an increase in urinary concentration and excretion of FABP and osteopontin with urine. Conclusions: The experiment revealed the renal dysfunction in the course of cyclophosphamide-induced cystitis with the tubulopathy character, expressed by the increased production and release into the urine two markers reflecting acute kidney injury – FABP and osteopontin.

References

• 1. Arms L., Vizzard M.A.: Role for pAKT in rat urinary bladder with cyclophosphamide (CYP)-induced cystitis. Am. J. Physiol. Renal Physiol., 2011; 301(2): F252–F262
  Google Scholar
• 2. Beker B.M., Corleto M.G., Fieiras C., Musso C.G.: Novel acute kidney injury biomarkers: their characteristics, utility and concerns. Int. Urol. Nephrol., 2018; 50(4): 705–13
  Google Scholar
• 3. Brummaier T., Pohanka E., Studnicka-Benke A., Pieringer H.: Using cyclophosphamide in inflammatory rheumatic diseases. Eur. J. Intern. Med., 2013; 24: 590–6
  Google Scholar
• 4. Chawla L.S., Ronco C.: Renal stress testing in the assessment of kidney disease. Kidney Int. Rep., 2016; 1(1): 57–63
  Google Scholar
• 5. Choundhury D., Ahmed Z.: Drug-associated renal dysfunction and injury. Nat. Clin. Pract. Nephrol., 2006; 2(2): 80–91
  Google Scholar
• 6. Ciach E., Bobilewicz D.: The use of cystatin C concentration in the assessment of glomerular filtration rate in children and elderly population . J. Lab. Diagn., 2012; 48(4): 423–31
  Google Scholar
• 7. Decloedt E., Maartens G.: Drug-induced renal injury. CME, 2011; 29(6): 252–5
  Google Scholar
• 8. Dhodi D.K., Bhagat S.B., Pathak D., Patel S.B.: Drug-induced nephrotoxicity. Int. J. Basic Clin. Pharmacol., 2014; 3(4): 591–7
  Google Scholar
• 9. Dobrek Ł., Skowron B., Baranowska A., -Malska-Woźniak A., Thor P.: Urinary kidney injury molecule-1 (KIM-1) excretion in rats with experimental cystitis induced by oxazaphosphorines. Przegl. Lek., 2016; 73(11): 805–12
  Google Scholar
• 10. Dobrek Ł., Thor P.: Novel biomarkers of acute kidney injury and chronic kidney disease. Pol. Ann. Med., 2017; 24: 84–91
  Google Scholar
• 11. Dobrek Ł., Thor P.J.: Selected proteins as biomarkers of kidney injury used in the nephrological diagnosis. Post. Bioch., 2016; 62(4): 482–94
  Google Scholar
• 12. Emadi A., Jones R.J., Brodsky R.A.: Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol., 2009; 6(11): 638–47
  Google Scholar
• 13. Estakhri R., Hajipour B., Majidi H., Soleimani H.: Vitamin E ameliorates cyclophosphamide induced nephrotoxicity. Life Sci. J., 2013; 10(6s): 308–13
  Google Scholar
• 14. Fu D., Ye S., Xiao C., Xie Y., Gao J., Liang L., Yang X.: Incidence of cyclophosphamide-induced hemorrhagic cystitis in Chinese Han population with autoimmune disease. Int. J. Clin. Exp. Med., 2016; 9(7): 13160–5
  Google Scholar
• 15. Gandhi J., Seyam O., Smith N.L., Joshi G., Vatsia S., Khan S.A.: Clinical utility of hyperbaric oxygen therapy in genitourinary medicine. Med. Gas. Res., 2018; 8(1): 29–33
  Google Scholar
• 16. Ghosh S., Ghosh D., Chattopadhyay S., Debnath J.: Effect of ascorbic acid supplementation on liver and kidney toxicity in cyclophosphamide-treated female albino rats. J. Toxicol. Sci., 1999; 24(3): 141–4
  Google Scholar
• 17. Guo H., Cai C.Q., Schroeder R.A., Kuo P.C.: Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J. Immunol., 2001; 166(2): 1079–86
  Google Scholar
• 18. Herrera J., Rodriguez-Iturbe B.: Stimulation of tubular secretion of creatinine in health and in conditions associated with reduced nephron mass. Evidence for a tubular functional reserve. Nephrol. Dial. Transplant., 1998; 13(3): 623–9
  Google Scholar
• 19. Higgins C.: Urea and the clinical value of measuring blood urea concentration. https://acutecaretesting.org/~/media/acutecaretesting/files/pdf/urea-and-the-clinical-value-of-measuring-blood-ans-approved.pdf (07.01.2018)
  Google Scholar
• 20. Jurado J.M., Sánchez A., Pajares B., Pérez E., Alonso L., Alba E.: Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin. Transl. Oncol., 2008; 10(9): 583–6
  Google Scholar
• 21. Kamijo-Ikemori A., Sugaya T., Kimura K.: Urinary fatty acid binding protein in renal disease. Clin. Chim. Acta, 2006; 374(1–2): 1–7
  Google Scholar
• 22. Kim J., Chan J.J.: Cyclophosphamide in dermatology. Australas. J. Dermatol., 2017; 58(1): 5–17
  Google Scholar
• 23. Kim S., Choi H.J., Jo C.H., Park J.S., Kwon T.H., Kim G.H.: Cyclophosphamide-induced vasopressin-independent activation of aquaporin-2 in the rat kidney. Am. J. Physiol. Renal Physiol., 2015; 309: F454–F483
  Google Scholar
• 24. Kim S., Jo C.H., Park J.S., Han H.J., Kim G.H.: The role of proximal nephron in cyclophosphamide-induced water retention: preliminary data. Electrolyte Blood Press., 2011; 9(1): 7–15
  Google Scholar
• 25. Kim S.Y., Moon A.: Drug-induced nephrotoxicity and its biomarkers. Biomol. Ther., 2012; 20(3): 268–72
  Google Scholar
• 26. Knights K.M., Rowland A., Miners J.O.: Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br. J. Clin. Pharmacol., 2013; 76(4): 587–602
  Google Scholar
• 27. Lameire N.: Nephrotoxicity of recent anti-cancer agents. Clin. Kidney J., 2014; 7(1): 11–22
  Google Scholar
• 28. Lopez-Giacoman S., Madero M.: Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J. Nephrol., 2015; 4(1): 57–73
  Google Scholar
• 29. Matz E.L., Hsieh M.H.: Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis. Urology, 2017; 100: 16–9
  Google Scholar
• 30. McMahon B.A., Murray P.T.: Urinary liver fatty acid binding protein: another novel biomarker of acute kidney injury. Kidney Int., 2010; 77(8): 657–9
  Google Scholar
• 31. Mohamaden W.I., Wang H., Guan H., Meng X., Li J.: Osteopontin and Tamma Horsefall proteins – macromolecules of myriad values. J. Basic Appl. Zool., 2014; 67(5): 158–63
  Google Scholar
• 32. Monach P.A., Arnold L.M., Merkel P.A.: Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum., 2010; 62(1): 9–21
  Google Scholar
• 33. Morais M.M., Belarmino-Filho J.N., Brito G.A., Ribeiro R.A.: Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis – comparison of the effects of dexamethasone and mesna. Braz. J. Med. Biol. Res., 1999; 32(10): 1211–5
  Google Scholar
• 34. Ostermann M.: Diagnosis of acute kidney injury: Kidney Disease Improving Global Outcomes criteria and beyond. Curr. Opin. Crit. Care, 2014; 20(6): 581–7
  Google Scholar
• 35. Payne H., Adamson A., Bahl A., Borwell J., Dodds D., Health C., Huddart R., McMenemin R., Patel P., Peters J.L., Thompson A.: Chemical and radiation-induced haemorrhagic cystitis: current treatments and challenges. BJU Int., 2013; 112(7): 885–97
  Google Scholar
• 36. Perazella M., Moeckel G.W.: Nephrotoxicity from chemiotherapeutic agents: clinical manifestations, pathobiology and prevention/therapy. Semin. Nephrol., 2010; 30(6): 570–81
  Google Scholar
• 37. Perazella M.A.: Renal vulnerability to drug toxicity. Clin. J. Am. Soc. Nephrol., 2009; 4(7): 1275–83
  Google Scholar
• 38. Ponticelli C., Escoli R., Moroni G.: Does cyclophosphamide still play a role in glomerular diseases? Autoimmun. Rev., 2018; 17(10): 1022–7
  Google Scholar
• 39. Pozzoli S., Simonini M., Manunta P.: Predicting acute kidney injury: current status and future challenges. J. Nephrol., 2018; 31(2): 209–23[40] Rysz J., Gluba-Brzózka A., Franczyk B., Jabłonowski Z., Ciałkowska-Rysz A.: Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int. J. Mol. Sci., 2017; 18(8): E1702
  Google Scholar
• 41. Schröder A., Newgreen D., Andersson K.E.: Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice. J. Urol., 2004; 172(3): 1166–70
  Google Scholar
• 42. Senthilkumar S., Devaki T., Manohar B.M., Babu M.S.: Effect of squalene on cyclophosphamide-induced toxicity. Clin. Chim. Acta, 2006; 364(1–2): 335–42
  Google Scholar
• 43. Shahana A.A., Karale S., Kamath J.V.: Nephroprotective effect of Mentha longifolia against cyclophosphamide-induced nephrotoxicity in rats: a biochemical and histological study. Int. Res. J. Pharm., 2016; 7(6): 77–82
  Google Scholar
• 44. Sinanoglu O., Yener A.N., Ekici S., Midi A., Aksungar F.B.: The protective effects of spirulina in cyclophosphamide induced nephrotoxicity and urotoxicity in rats. Urology, 2012; 80(6): 1392.e1–6
  Google Scholar
• 45. Stefanowicz J., Ruckemann-Dziurdzińska K., Owczuk J., Iżycka-Świeszewska E., Balcerska A.: Nephrotoxicity of nitrogen mustard derivatives (ifosfamide, cyclophosphamide, trofosfamide) in children. Nefrol. Dial. Pol., 2011; 15: 247–51
  Google Scholar
• 46. Sugino Y., O’Malley K.J., Wang Z., Tyagi P., Birder L.A., Ogawa O., Yoshimura N.: Laser-capture microdissection for analysis of cell type-specific gene expression of muscarinic receptor subtypes in the rat bladder with cyclophosphamide-induced cystitis. Int. Urol. Nephrol., 2015; 47(4): 637–42
  Google Scholar
• 47. Sugumar E., Kanakasabapathy I., Abraham P.: Normal plasma creatinine level despite histological evidence of damage and increased oxidative stress in the kidneys of cyclophosphamide treated rats. Clin. Chim. Acta, 2007; 376(1–2): 244–5
  Google Scholar
• 48. Teo S.H., Endre Z.H.: Biomarkers in acute kidney injury (AKI). Best Pract. Res. Clin. Anaesthesiol., 2017; 31(3): 331–44
  Google Scholar
• 49. Veal G.J., Cole M., Chinnaswamy G., Sludden J., Jamieson D., Errington J., Malik G., Hill C.R., Chamberlain T., Boddy A.V.: Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. Eur. J. Cancer, 2016; 55: 56–64
  Google Scholar
• 50. Wai P.Y., Guo L., Gao C., Mi Z., Guo H., Kuo P.C.: Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery, 2006; 140(2): 132–40
  Google Scholar
• 51. Wang H., Tompkins L.M.: CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab., 2008; 9(7): 598–610
  Google Scholar
• 52. Wu H., Huang J.: Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies. Curr. Drug Metab., 2018; 19(7): 559–67
  Google Scholar
• 53. Xu X., Malavé A.: Protective effect of berberine on cyclophosphamide-induced haemorrhagic cystitis in rats. Pharmacol. Toxicol., 2001; 88(5): 232–7
  Google Scholar
• 54. Yim H.E., Yoo K.H.: Osteopontin and developing kidney. J. Korean Soc. Pediatr. Nephrol., 2006; 10(1): 1–7
  Google Scholar
• 55. Zanger U.M., Klein K.: Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front. Genet., 2013; 4: 24
  Google Scholar
• 56. Zeng J., Pan C., Jiang C., Lindström S.: Cause of residual urine in bladder outlet obstruction: an experimental study in the rat. J. Urol., 2012; 188(3): 1027–32
  Google Scholar
• 57. Zimmerman A.W., Veerkamp J.H.: New insights into the structure and function of fatty acid-binding proteins. Cell. Mol. Life Sci., 2002; 59(7): 1096–116
  Google Scholar

Full text